Form 4: Precision Biosciences Director Increases Equity Holdings Through RSU Vesting and New Grant

Stanley Frankel, a Director at Precision Biosciences Inc. (DTIL), reported an increase in his beneficial ownership of common stock and a new grant of Restricted Stock Units (RSUs) through recent transactions.

Summary

• On May 27, 2025, Stanley Frankel, a Director of Precision Biosciences Inc. (DTIL), acquired 9,826 shares of common stock through the vesting of previously granted Restricted Stock Units (RSUs).
• Following this vesting, Mr. Frankel's direct beneficial ownership of Precision Biosciences common stock increased to 14,078 shares.
• Additionally, on June 3, 2025, Mr. Frankel was granted 21,000 new Restricted Stock Units (RSUs).
• These newly granted RSUs are contingent rights to receive one share of common stock per RSU and are set to vest on the earlier of June 3, 2026, or the day immediately prior to the Issuer's next annual meeting of stockholders, subject to his continued service.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive as a director increasing their equity stake, through both vesting and new grants, generally signals confidence in the company's future and aligns their interests with shareholders. This is a routine compensation event but still carries a positive undertone.

Positives

• The vesting of RSUs and the grant of new RSUs to a director indicate continued alignment of management's interests with those of shareholders.
• An increase in a director's equity holdings can be perceived as a vote of confidence in the company's future prospects.

Future Outlook

The document does not provide a general future outlook for the company, but it does specify future vesting conditions for the newly granted Restricted Stock Units, indicating a continued service requirement for the director.

Industry Context

This Form 4 filing reflects standard equity compensation practices for directors in publicly traded biotechnology or life sciences companies like Precision Biosciences, aiming to align executive incentives with long-term shareholder value.

Stakeholder Impact

• Shareholders: The increase in a director's equity ownership can be viewed positively, as it strengthens the alignment of management's interests with shareholder value creation.
• Employees: While not directly impacting all employees, the compensation structure for directors can reflect broader company policies regarding equity incentives.

Next Steps

• The 21,000 Restricted Stock Units granted on June 3, 2025, are expected to vest on the earlier of June 3, 2026, or the day immediately prior to the Issuer's next annual meeting of stockholders, subject to Stanley Frankel's continued service.

Key Dates

Keywords

Precision Biosciences, DTIL, Stanley Frankel, SEC Form 4, Insider Trading, Restricted Stock Units, RSU Vesting, Equity Grant, Director Compensation, Beneficial Ownership